Zymeworks Highlights Early Data From Zanidatamab Zovodotin Trial In HER2-Positive Tumors
Benzinga · 09/13/2022 13:34
  • Zymeworks Inc (NASDAQ:ZYMEpresented preliminary results from its Phase 1 trial evaluating zanidatamab zovodotin (ZW49) for HER2-positive tumors. 
  • The data were presented at the European Society for Medical Oncology Annual Congress.
  • A total of 77 patients were enrolled in this first-in-human trial, designed to determine the maximum tolerated dose of zanidatamab zovodotin, characterize its safety and tolerability, and evaluate anti-tumor activity in HER2-expressing cancers as monotherapy. 
  • Also Read: Zymeworks Turns Down All Blue's Hostile Bid.
  • At the time of the analysis, the maximum tolerated dose had not yet been reached.
  • In the trial, zanidatamab zovodotin was shown to have a manageable safety profile, with the majority of adverse events being mild or moderate.
  • In patients with HER2-positive cancers treated with zanidatamab zovodotin at 2.5 mg/kg Q3W, the confirmed objective response rate was 31%, and the disease control rate was 72%. 
  • The Phase 1 trial continues to enroll patients to study safety. The company expects to present the results of this dosing regimen at a medical meeting in 2023.
  • Price Action: ZYME shares are up 0.20% at $4.95 during the market session on the last check Tuesday.